Compare Bristol-Myers Squibb Co (BMY) vs Dover Corp (DOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Dover Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.8 (market cap $129.94B), while Dover Corp trades at $207.85 (market cap $28.07B). The key difference: Bristol-Myers Squibb Co is far larger — about 4.6× Dover Corp's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | DOV | |
|---|---|---|
Market Cap | $129.94B | $28.07B |
Sector | Health | Industrials |
52-Week High | $65.89 | $233.31 |
52-Week Low | $42.60 | $161.16 |
Enterprise Value | $163.92B | $29.58B |
Dividend Yield | 3.96% | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
DOV trades at $207.92, down 1.04% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten EPS estimates for three consecutive quarters, maintains a 13.48% net income margin, and recently raised its dividend. Analyst consensus is strongly bullish with a $232.33 price target. Recent news highlights manufacturing strength and strategic acquisitions like Cloeren, supporting growth in data center and AI segments.
The outlook is positive given earnings momentum, dividend growth, and raised 2026 guidance. Risks include market volatility and execution of acquisitions. With no sell ratings and solid cash flow, DOV offers a balanced opportunity for growth and income, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →
